AI drug discovery
The platform offers AI models and agents that help scientists design, test and iterate experiments to identify and analyze potential antibody therapies.
The pharma giant will deploy OpenAI's most advanced capabilities across its global operations, from drug discovery to commercial functions, and upskill its workforce in AI literacy.
The deal grants Lilly exclusive global rights to use Insilico's Pharma.AI platform for drug discovery and development across multiple therapeutic areas.
The pharma giant’s AI factory combines on-premises and cloud GPU infrastructure, leveraging more than 3,500 Blackwell GPUs for AI-driven drug discovery and research.
The San Francisco-based lab will house Eli Lilly experts in biology, science and medicine alongside NVIDIA AI model builders and engineers.
Genentech will leverage Medra's Physical AI, Scientific AI and robotics into its lab systems to accelerate drug discovery.
The funds will be used to advance Insilico's drug pipeline and lab, which automates the research and development process, and refine its AI-enabled models and algorithms.
The company, in partnership with Microsoft, aims to develop cancer medicines, followed by treatments for autoimmune diseases and rare conditions.
AMD is making a $20 million equity investment to bolster Absci's drug discovery efforts and expand AMDs accelerators and ROCm software.
The partnership highlights the broader trend of AI-driven innovation in drug discovery and precision medicine.